VISTA PHARMACEUTICALS LTD. - 524711 - Announcement under Regulation 30 (LODR)-Allotment
Announcement of Outcome of Board Meeting pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("SEBI LODR Regulations). VISTA PHARMACEUTICALS LTD. - 524711 - Announcement under Regulation 30 (LODR)-Allotment
Allotment of 3,33,333 Equity Shares on conversion of 3,33,333 warrants to the other on preferential basis VISTA PHARMACEUTICALS LTD. - 524711 - Closure of Trading Window
Intimation for closure of Trading Window for the Quarter ended 30th June, 2023. VISTA PHARMACEUTICALS LTD. - 524711 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Pursuant to Regulation 30 of the Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements) Regulations, 2015 ["Listing Regulations"), we hereby inform that the Board of Directors of the Company at its meeting held today i.e. June 16,2023 has accepted the resignation of Mr. Nishant Talreja (CS Membership No. A 71531) from the post of Company Secretary ,Compliance Officer and Key Managerial Personnel (KMP) of the Company, due to personal reasons. with effect from the closing of business hours of Friday, June 16, 2023. VISTA PHARMACEUTICALS LTD. - 524711 - Announcement under Regulation 30 (LODR)-Allotment
This is to inform the Exchange(s) that pursuant to the special resolution passed by the members of the Company under Section 62 of the Companies Act, 2013 on 14th October, 2022 and In- principle approval received from BSE on 30.11.2022, and the allotment of warrants dated 14th December 2022, the allotment of 6,96,870 equity shares of Rs.2/- in the Company's Equity Share Capital, on conversion of 6,96,870 Warrants, be and are hereby allotted to the person as mentioned below at a price of Rs.10/- per equity shares includes a premium of Rs.8/- per share: for which the Board of Directors have accorded their approval, at their meeting held on 09th June, 2023 Commenced at 03.00 P.M and Concluded at 03.30 P.M. Sl. No Name of the Allottee No of Equity Shares 1. Mr. Murali Marega (Managing Director) 4,96,870 2. Mr. Pavan Sathvik Gilaka (Whole Time Director) 2,00,000 Total 6,96,870 VISTA PHARMACEUTICALS LTD. - 524711 - Statement Of Deviation Or Variation In Utilization Of Funds Raised Through Preferential Issue Of Equity Shares Of The Company For The Quarter Ended On March 31St 2023.
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD1/16212019 dated December 24, 2019 please find enclosed herewith the Statement of Deviation or Variation in utilization of funds raised through preferential issue of Equity Shares of the Company for the quarter ended on March 3lst,2023. Kindly take the same on record and acknowledge the receipt of the same. VISTA PHARMACEUTICALS LTD. - 524711 - Financial Results For The Quarter And Year Ended 31St March, 2023- Regulation 33 (3) (A).
With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Tuesday, 30.05.2023 at 04.00 P.M at the registered address of the Company, interalia, considered and approved the audited Financial Results for the quarter and year ended 31st March, 2023. Copy of audited Financial Results for the quarter and year ended 31st March, 2023 and Audited Report is enclosed herewith. VISTA PHARMACEUTICALS LTD. - 524711 - Board Meeting Outcome for Outcome Of Board Meeting - Reg 30
With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its Meeting held on Tuesday, 30.05.2023 at 04.00 P.M and ended at 10.00 P.M at the corporate office of the Company inter-alia considered and approved the following: 1. Audited Financial Results for the quarter and year ended 31st March, 2023. 2. Auditors Report for the quarter and year ended 31st March, 2023. 3. Appointment of Secretarial Auditor of the Company for Financial Year 2022-23. 4. Appointment of Internal Auditor of the Company for the Financial Year 2023-24. 5. Appointment of Company Secretary and Compliance Officer of the Company. VISTA PHARMACEUTICALS LTD. - 524711 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In compliance with Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 and SEBI Circular No. CIR/CFD/CMD/27/2019 dated February 8, 2019, please find enclosed herewith copy of Annual Secretarial Compliance Report dated May 30, 2023 for the Financial Year 2022-23 issued by our Secretarial Auditor, N.V.S.S. Suryanarayana, Practicing Company Secretary.